Literature DB >> 15928615

Cutaneous leishmaniasis in soldiers from Fort Campbell, Kentucky returning from Operation Iraqi Freedom highlights diagnostic and therapeutic options.

Robert J Willard1, Anelia M Jeffcoat, Paul M Benson, Douglas S Walsh.   

Abstract

BACKGROUND: Cutaneous leishmaniasis (CL), rare in the first Gulf War, is common in American troops serving in Operation Iraqi Freedom. Awareness of the clinical features and treatment options of CL would benefit clinicians who may encounter soldiers, as well as civilians, returning from the Middle East with skin lesions.
OBJECTIVE: Our purpose was to describe our clinical experience in treating soldiers with CL.
METHODS: From December 2003 through June 2004, approximately 360 of an estimated 20,000 soldiers returning from a yearlong deployment in Iraq with skin lesions suspected of being CL were examined by dermatologists. We summarized CL diagnoses, laboratory evaluations, and treatments, including localized heat therapy (ThermoMed model 1.8; ThermoSurgery Technologies, Inc, Phoenix, Ariz), oral fluconazole, cryotherapy, and itraconazole.
RESULTS: Among 237 soldiers diagnosed with CL, 181 had one or more laboratory confirmations, most by Giemsa-stained lesion smears and polymerase chain reaction (PCR). PCR was positive for all 122 smear-positive and 26 biopsy-positive lesions and all 34 smear negative and all 3 biopsy-negative cases. Primary outpatient treatments, including ThermoMed (n = 26), oral fluconazole (n = 15), cryotherapy (n = 4), and itraconazole (n = 2), were safe and tolerable. Treatment failure occurred in 2 fluconazole recipients and was suspected in 1 ThermoMed and 2 fluconazole recipients. Seventy-two soldiers elected no treatment. LIMITATION: This was a retrospective study.
CONCLUSION: Approximately 1% of Ft Campbell troops returning from Iraq were diagnosed with CL, most by laboratory confirmation. PCR appeared to be the most useful diagnostic technique. Among outpatient treatments, ThermoMed and cryotherapy had favorable safety and efficacy profiles.

Entities:  

Mesh:

Year:  2005        PMID: 15928615     DOI: 10.1016/j.jaad.2005.01.109

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

1.  Old World cutaneous leishmaniasis: diagnosis and treatment.

Authors:  Abderrahmen Masmoudi; Wala Hariz; Slaheddine Marrekchi; Mariem Amouri; Hamida Turki
Journal:  J Dermatol Case Rep       Date:  2013-06-30

2.  A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection.

Authors:  Naomi E Aronson; Glenn W Wortmann; William R Byrne; Robin S Howard; Wendy B Bernstein; Mary A Marovich; Mark E Polhemus; In-Kyu Yoon; Kelly A Hummer; Robert A Gasser; Charles N Oster; Paul M Benson
Journal:  PLoS Negl Trop Dis       Date:  2010-03-09

Review 3.  Gulf war servicemen and servicewomen: the long road home and the role of health care professionals to enhance the troops' health and healing.

Authors:  Robin B McFee
Journal:  Dis Mon       Date:  2008-05       Impact factor: 3.800

4.  The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.

Authors:  Quaovi Sodji; Vishal Patil; Surendra Jain; James R Kornacki; Milan Mrksich; Babu L Tekwani; Adegboyega K Oyelere
Journal:  Bioorg Med Chem Lett       Date:  2014-09-04       Impact factor: 2.823

5.  Successful treatment of canine cutaneous leishmaniasis using radio-frequency induced heat (RFH) therapy.

Authors:  Anil A Ahuja; Ram A Bumb; Rajesh D Mehta; Neha Prasad; Ram K Tanwar; Abhay R Satoskar
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

6.  Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.

Authors:  Liliana López; Martha Robayo; Margarita Vargas; Iván D Vélez
Journal:  Trials       Date:  2012-05-17       Impact factor: 2.279

7.  Novel low-cost thermotherapy for cutaneous leishmaniasis in Peru.

Authors:  Braulio M Valencia; David Miller; Richard S Witzig; Andrea K Boggild; Alejandro Llanos-Cuentas
Journal:  PLoS Negl Trop Dis       Date:  2013-05-02

8.  Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.

Authors:  Néstor Sosa; Zeuz Capitán; Javier Nieto; Melissa Nieto; José Calzada; Hector Paz; Carmenza Spadafora; Mara Kreishman-Deitrick; Karen Kopydlowski; Diane Ullman; William F McCarthy; Janet Ransom; Jonathan Berman; Charles Scott; Max Grogl
Journal:  Am J Trop Med Hyg       Date:  2013-07-15       Impact factor: 2.345

9.  The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate.

Authors:  Mohammad Omidian; Maryam Jadbabaei; Ehsan Omidian; Zahra Omidian
Journal:  Postepy Dermatol Alergol       Date:  2019-02-20       Impact factor: 1.837

Review 10.  Efficacy of azole therapy for tegumentary leishmaniasis: A systematic review and meta-analysis.

Authors:  Endi Lanza Galvão; Ana Rabello; Gláucia Fernandes Cota
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.